HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Warner-Lambert

This article was originally published in The Rose Sheet

Executive Summary

Divestiture of one overlapping consumer brand marketed in the U.S. required to receive Federal Trade Commission approval, Pfizer announces. Although the company declined to specifically name FTC's area of concern, it appears most likely Warner-Lambert's Nix and Pfizer's Rid pediculicides would need to be divested. One of the other few potential overlapping areas is mouthwash - W-L markets Listerine and Pfizer sells Plax. The agreement with FTC also involves the divestiture of one early clinical candidate for which the companies have overlapping research programs, Pfizer said. The closing is targeted for early to mid-June, according to Pfizer

You may also be interested in...



Bayer Rid Pediculicide Marketing Emphasis On Mousse Launch

Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
UsernamePublicRestriction

Register

RS008053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel